In 67 adults with overweight/obesity and MASLD or MASH, weekly DD01 40 mg gave ≥30% relative liver fat reduction on MRI-PDFF at 12 weeks in 76% vs 12% with placebo (RR 6·3). Nausea 55% vs 18%; 2 serious events with DD01. Prespecified 12-week analysis.
RCTn = 67
Noureddin et al. The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial